This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kruczynski, A. Articles by Hill, B. T. Search for Related Content PubMed PubMed Citation Articles by Kruczynski, A. Articles by Hill, B. T.

Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase II Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II

Division of Experimental Cancer Research, Pierre Fabre Research Center, Castres, Cedex, France

Purpose: The purpose of the study was to investigate the mechanisms associated with antitumor activity and resistance to F11782, a novel dual catalytic inhibitor of topoisomerases with DNA repair-inhibitory properties.

Experimental Design: For that purpose, an F11782-resistant P388 leukemia subline (P388/F11782) has been developed in vivo and characterized.

Results: Weekly subtherapeutic doses of F11782 (10 mg/kg) induced complete resistance to F11782 after 8 weekly passages. This resistant P388/F11782 subline retained some in vivo sensitivity to several DNA-topoisomerase II and/or I complex-stabilizing poisons and showed marked collateral sensitivity to cisplatin, topotecan, colchicine, and Vinca alkaloids, while proving completely cross-resistant only to merbarone and doxorubicin. Therefore, resistance to F11782 did not appear to be associated with a classic multidrug resistance profile, as further reflected by unaltered drug uptake and no overexpression of resistance-related proteins or modification of the glutathione-mediated detoxification process. In vivo resistance to F11782 was, however, associated with a marked reduction in topoisomerase II protein (87%) and mRNA (50%) levels, as well as a diminution of the catalytic activity of topoisomerase II. In contrast, only minor reductions in topoisomerases IIß and I levels were recorded. However, of major interest, nucleotide excision repair activity was decreased 3-fold in these P388/F11782 cells and was more specifically associated with a decreased (67%) level of XPG (human xeroderma pigmentosum group G complementing protein), an endonuclease involved in this DNA repair system.

Conclusions: These findings suggest that both topoisomerase II and XPG are major targets of F11782 in vivo and further demonstrate the original mechanism of action of this novel compound.

This article has been cited by other articles:

				D. C. Marchion, E. Bicaku, J. G. Turner, A. I. Daud, D. M. Sullivan, and P. N. Munster Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase II{beta} Clin. Cancer Res., December 1, 2005; 11(23): 8467 - 8475. [Abstract] [Full Text] [PDF]